Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 133 results for hepatitis

  1. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  2. Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (IPG258)

    Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.

  3. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  4. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)

    NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .

  5. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (HTG353)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.

  6. Methadone and buprenorphine for the management of opioid dependence (TA114)

    Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.

  7. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

  8. How cost effective are cohort testing programmes: - as a stand-alone programme, or - as an extension of the NHS Health Check programme?

    None. Source guidance details Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43

  9. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  10. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  11. Caesarean birth (NG192)

    This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.

  12. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    clinical data from people having treatment with the new generation of hepatitis C virus treatments. NICE agreed that such efforts should...

  13. What are the risks that predict the development of blood-borne virus infections in people with complex psychosis in the UK?

    diseases was based on evidence about the relatively high prevalence of hepatitis and HIV in people with severe mental illness. The...

  14. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

  15. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.